Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Introduction to Hemostasis01:05

Introduction to Hemostasis

8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
Coagulation01:09

Coagulation

7.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay.

Blood advances·2025
Same author

Red cell physiologic stress results in lower quality transfusions: a randomized trial in adults with sickle cell disease.

Blood. Red cells & iron·2025
Same author

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years.

Blood advances·2025
Same author

Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model.

Blood advances·2025
Same author

Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center.

Haemophilia : the official journal of the World Federation of Hemophilia·2024
Same journal

Author response to Zhang and Chen.

British journal of haematology·2026
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.1K

Fibrinolysis in a nutshell.

Anton Ilich1, Nigel S Key1,2

  • 1UNC Blood Research Center, Chapel Hill, North Carolina, USA.

British Journal of Haematology
|August 5, 2025
PubMed
Summary
This summary is machine-generated.

Fibrinolysis is the enzymatic breakdown of blood clots. Key steps involve tissue plasminogen activator (tPA) converting plasminogen to plasmin, which then degrades fibrin, the main clot component.

Keywords:
fibrinfibrinolysisplasmintranexamic acid

More Related Videos

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.6K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K

Related Experiment Videos

Last Updated: Sep 12, 2025

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

1.1K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

11.6K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

2.8K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Fibrinolysis is crucial for dissolving blood clots.
  • The process involves enzymatic degradation of fibrin.
  • Regulation by inhibitors and clot structure is essential.

Purpose of the Study:

  • To provide a brief overview of the fibrinolysis process.
  • To highlight the enzymatic cascade involved in clot degradation.
  • To mention the regulatory mechanisms of fibrinolysis.

Main Methods:

  • Literature review of fibrinolysis mechanisms.
  • Description of the enzymatic pathway.
  • Discussion of regulatory factors.

Main Results:

  • Fibrinolysis involves the enzymatic degradation of fibrin.
  • Tissue plasminogen activator (tPA) plays a key role.
  • Plasminogen is converted to plasmin, which digests fibrin.
  • Clot architecture and inhibitors tightly regulate the process.

Conclusions:

  • Fibrinolysis is a tightly regulated enzymatic process essential for hemostasis.
  • The tPA-plasminogen complex formation is central to fibrin degradation.
  • Understanding fibrinolysis is vital, with implications beyond clot dissolution.